SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Krobitsch Sylvia)
 

Sökning: WFRF:(Krobitsch Sylvia) > The citrullinated/n...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007499naa a2200685 4500
001oai:DiVA.org:uu-456854
003SwePub
008211025s2021 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:147585996
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4568542 URI
0247 a https://doi.org/10.1186/s13075-021-02603-x2 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1475859962 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Marklein, Biankau Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Charite Campus Mitte, Rheumatol Forschungslab AG Skriner, Charitepl 1,Intern Virchowweg 11,5-OG,R011, D-10117 Berlin, Germany4 aut
2451 0a The citrullinated/native index of autoantibodies against hnRNP-DL predicts an individual "window of treatment success" in RA patients
264 c 2021-09-14
264 1b BioMed Central (BMC),c 2021
338 a electronic2 rdacarrier
500 a Correction in: Arthritis Research & Therapy, Volume 23, Issue 1, Article Number 255, DOI 10.1186/s13075-021-02639-z
520 a BackgroundThere is a need for biomarker to identify patients “at risk” for rheumatoid arthritis (risk-RA) and to better predict the therapeutic response and in this study we tested the hypothesis that novel native and citrullinated heterogeneous nuclear ribonucleoprotein (hnRNP)-DL autoantibodies could be possible biomarkers.MethodsUsing protein macroarray and ELISA, epitope recognition against hnRNP-DL was analysed in sera from different developed RA disease and diagnosed SLE patients. Toll-like receptor (TLR) 7/9 and myeloid differentiation primary response gene 88 (MyD88)-dependency were studied in sera from murine disease models. HnRNP-DL expression in cultivated cells and synovial tissue was analysed by indirect immunofluorescence, immunoblot and immunohistochemistry.ResultsHnRNP-DL was highly expressed in stress granules, citrullinated in the rheumatoid joint and targeted by autoantibodies either as native or citrullinated proteins in patient subsets with different developed RA disease. Structural citrullination dependent epitopes (SCEs) of hnRNP-DL were detected in 58% of the SLE patients although 98% of these sera were α-CCP-2-negative. To obtain a specific citrullinated signal value, we subtracted the native antibody value from the citrullinated signal. The citrullinated/native index of autoantibodies against hnRNP-DL (CNDL-Index) was identified as a new value for an “individual window of treatment success” in early RA and for the detection of RF IgM/α-CCP-2 seronegative RA patients (24–46%). Negative CNDL-index was found in SLE patients, risk-RA and early RA cohorts such as EIRA where the majority of these patients are DAS28-responders to methotrexate (MTX) treatment (87%). High positive CNDL-values were associated with more severe RA, shared epitope and parenchymal changes in the lung. Specifically, native α-hnRNP-DL is TLR7/9-dependent, associated with pain and ROC analysis revealed an association to initial MTX or etanercept treatment response, especially in seronegative RA patients.ConclusionCNDL-index defines people at risk to develop RA and the “window of treatment success” thereby closing the sensitivity gap in RA.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng
653 a Rheumatoid arthritis
653 a ACPA
653 a Anti-CCP
653 a Rheumatoid factor
653 a Shared epitope
653 a Systemic lupus erythematosus
653 a Autoantigens
653 a Treatment
7001 a Jenning, Madeleineu Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Charite Campus Mitte, Rheumatol Forschungslab AG Skriner, Charitepl 1, Intern Virchowweg 11, 5-OG, R011, D-10117 Berlin, Germany; Leibniz Inst, German Rheumatism Res Ctr, D-10117 Berlin, Germany4 aut
7001 a Konthur, Zoltánu Max Planck Inst Mol Genet, Berlin, Germany; Max Planck Inst Colloids & Interfaces, Potsdam, Germany; Bundesanstalt Mat Forsch & Prufung BAM, Dept Analyt Chem, Dept 1, Berlin, Germany4 aut
7001 a Häupl, Thomasu Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Charite Campus Mitte, Rheumatol Forschungslab AG Skriner, Charitepl 1,Intern Virchowweg 11,5-OG,R011, D-10117 Berlin, Germany4 aut
7001 a Welzel, Franziskau Max Planck Inst Mol Genet, Berlin, Germany4 aut
7001 a Nonhoff, Uteu Max Planck Inst Mol Genet, Berlin, Germany4 aut
7001 a Krobitsch, Sylviau Max Planck Inst Mol Genet, Berlin, Germany4 aut
7001 a Mulder, Debbie M.u Radboud Univ Nijmegen, Dept Expt Rheumatol, Med Ctr, Nijmegen, Netherlands4 aut
7001 a Koenders, Marije I.u Radboud Univ Nijmegen, Dept Expt Rheumatol, Med Ctr, Nijmegen, Netherlands4 aut
7001 a Joshua, Vijayu Karolinska Institutet4 aut
7001 a Cope, Andrew P.u Kings Coll London, Fac Life Sci & Med, Ctr Rheumat Dis, Sch Immunol & Microbial Sci, London, England4 aut
7001 a Shlomchik, Mark J.u Univ Pittsburgh, Dept Immunol, Sch Med, Pittsburgh, PA USA4 aut
7001 a Anders, Hans-Joachimu Ludwig Maximilian Univ Hosp, Nephrol Ctr, Med Clin & Policlin 4, Munich, Germany4 aut
7001 a Burmester, Gerd R.u Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Charite Campus Mitte, Rheumatol Forschungslab AG Skriner, Charitepl 1,Intern Virchowweg 11,5-OG,R011, D-10117 Berlin, Germany4 aut
7001 a Hensvold, Aaseu Karolinska Institutet4 aut
7001 a Catrina, Anca I.u Karolinska Inst, Karolinska Univ Hosp, Dept Med Solna, Div Rheumatol, Stockholm, Sweden4 aut
7001 a Rönnelid, Johanu Uppsala universitet,Klinisk immunologi4 aut0 (Swepub:uu)joharonn
7001 a Steiner, Günteru Med Univ Vienna, Div Rheumatol, Vienna, Austria; Ludwig Boltzmann Cluster Arthrit & Rehabil, Vienna, Austria4 aut
7001 a Skriner, Karlu Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Charite Campus Mitte, Rheumatol Forschungslab AG Skriner, Charitepl 1, Intern Virchowweg 11, 5-OG, R011, D-10117 Berlin, Germany; Leibniz Inst, German Rheumatism Res Ctr, D-10117 Berlin, Germany4 aut
7102 a Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Charite Campus Mitte, Rheumatol Forschungslab AG Skriner, Charitepl 1,Intern Virchowweg 11,5-OG,R011, D-10117 Berlin, Germanyb Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Charite Campus Mitte, Rheumatol Forschungslab AG Skriner, Charitepl 1, Intern Virchowweg 11, 5-OG, R011, D-10117 Berlin, Germany; Leibniz Inst, German Rheumatism Res Ctr, D-10117 Berlin, Germany4 org
7730 t Arthritis Research & Therapyd : BioMed Central (BMC)g 23:1q 23:1x 1478-6362
8564 u https://doi.org/10.1186/s13075-021-02603-xy Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1605783/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://arthritis-research.biomedcentral.com/track/pdf/10.1186/s13075-021-02603-x
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-456854
8564 8u https://doi.org/10.1186/s13075-021-02603-x
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:147585996

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy